EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Impact of COVID‐19 on Hematologic Cancer Patients: Insights From the Late Pandemic Phase

Daniele Caracciolo iD, Giuseppe D'Aquino, Caterina Froio, Caterina Romeo, Vincenzo Bosco, Giulia Pensabene, Ludovica Tedesco, Pierosandro Tagliaferri, Pierfrancesco Tassone

Cancer Medicine · 2025

DOI: 10.1002/cam4.71112 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Cancer Medicine, 2025. Verfasst von Daniele Caracciolo und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental and Clinical Medicine, Magna Græcia University, Campus Salvatore Venuta, Catanzaro, Italy. Hauptthemen laut MEDLINE: COVID-19, Hematologic Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The COVID‐19 pandemic significantly increased mortality risks for individuals with hematological malignancies. Patients and Methods We conducted a single‐center observational study, focusing on the late pandemic phase of the infection (2022–2023), to identify risk factors associated with COVID‐19 outcomes in vaccinated patients with hematological malignancies.

Results

Eighty‐five COVID‐19 cases were recorded among patients with hematological malignancies, primarily Multiple Myeloma (MM) (38.8%), chronic lymphocytic leukemia (CLL) (10.6%) and Non‐Hodgkin Lymphoma (NHL) (35.3%). Despite a high COVID‐19 vaccination rate (97.6%), severe/critical illness occurred in 23.5% of patients. The overall COVID‐19‐related mortality rate was 22.4%, with a 30‐day mortality rate of 11.8%. Although mortality rates significantly decreased over the observation time (27.7% vs. 16.7%), this trend was not confirmed in critical infection carriers.

Conclusion

Our data confirm that, despite a reduction in critical infections and overall mortality rates over time, patients with hematological malignancies remain at high risk during the endemic phase of SARS‐CoV‐2 infection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Hematologic NeoplasmsAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedCOVID-19 VaccinesRisk FactorsSARS-CoV-2

Stichwörter der Autor:innen

COVID‐19chronic lymphocytic leukemiahematologic malignancieslate pandemic phasemultiple myelomamyelodysplastic syndromenon‐Hodgkin lymphoma

Substanzen

COVID-19 Vaccines

Autor:innen und Institutionen

  • Department of Experimental and Clinical Medicine, Magna Græcia University, Campus Salvatore Venuta, Catanzaro, Italy.
  • Medical and Translational Oncology, AOU Renato Dulbecco, Catanzaro, Italy.
  • Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy.

ORCID-Profile: Daniele Caracciolo

Zitieren

APA

Caracciolo, D., D'Aquino, G., Froio, C., Romeo, C., Bosco, V., Pensabene, G., Tedesco, L., Tagliaferri, P., & Tassone, P. (2025). Impact of COVID‐19 on Hematologic Cancer Patients: Insights From the Late Pandemic Phase. Cancer Medicine. https://doi.org/10.1002/cam4.71112

Vancouver

Caracciolo D, D'Aquino G, Froio C, Romeo C, Bosco V, Pensabene G, et al. Impact of COVID‐19 on Hematologic Cancer Patients: Insights From the Late Pandemic Phase. Cancer Medicine. 2025. doi:10.1002/cam4.71112

BibTeX
@article{Caracciolo2025,
  author = {Caracciolo, Daniele and D'Aquino, Giuseppe and Froio, Caterina and Romeo, Caterina and Bosco, Vincenzo and Pensabene, Giulia and Tedesco, Ludovica and Tagliaferri, Pierosandro and Tassone, Pierfrancesco},
  title = {Impact of COVID‐19 on Hematologic Cancer Patients: Insights From the Late Pandemic Phase},
  journal = {Cancer Medicine},
  year = {2025},
  doi = {10.1002/cam4.71112}
}
Kostenlos starten →